Loading
A phase 1/2 trial of LBL-034 for Injection in multiple myeloma, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06049290 by Nanjing Leads Biolabs Co.,Ltd, with 342 participants planned, started 2023-10-20 and due to reach its primary completion in 2026-10-20. Interventions recorded: LBL-034 for Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/